These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16533209)

  • 1. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions.
    Correll GE; Futter GE
    Pain Med; 2006; 7(1):92-5. PubMed ID: 16533209
    [No Abstract]   [Full Text] [Related]  

  • 2. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 3. Ketamine followed by memantine for the treatment of major depression.
    Kollmar R; Markovic K; Thürauf N; Schmitt H; Kornhuber J
    Aust N Z J Psychiatry; 2008 Feb; 42(2):170. PubMed ID: 18197514
    [No Abstract]   [Full Text] [Related]  

  • 4. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression.
    Liebrenz M; Stohler R; Borgeat A
    World J Biol Psychiatry; 2009; 10(4 Pt 2):640-3. PubMed ID: 17853274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".
    Hashimoto K
    J Clin Psychopharmacol; 2009 Aug; 29(4):411-2; author reply 412. PubMed ID: 19593196
    [No Abstract]   [Full Text] [Related]  

  • 6. An update on the role of glutamate in the pathophysiology of depression.
    Mitchell ND; Baker GB
    Acta Psychiatr Scand; 2010 Sep; 122(3):192-210. PubMed ID: 20105149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents.
    Finkel JC; Pestieau SR; Quezado ZM
    J Pain; 2007 Jun; 8(6):515-21. PubMed ID: 17434801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How does ketamine elicit a rapid antidepressant response?
    Kavalali ET; Monteggia LM
    Curr Opin Pharmacol; 2015 Feb; 20():35-9. PubMed ID: 25462290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.
    Paul R; Schaaff N; Padberg F; Möller HJ; Frodl T
    World J Biol Psychiatry; 2009; 10(3):241-4. PubMed ID: 19224412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy.
    Goforth HW; Holsinger T
    J ECT; 2007 Mar; 23(1):23-5. PubMed ID: 17435569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depression of NMDA-receptor-mediated segmental transmission by ketamine and ketoprofen, but not L-NAME, on the in vitro neonatal rat spinal cord preparation.
    Lizarraga I; Chambers JP; Johnson CB
    Brain Res; 2006 Jun; 1094(1):57-64. PubMed ID: 16716267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do glutamatergic agents represent a new class of antidepressant drugs? Part 1.
    Sanacora G
    J Clin Psychiatry; 2009 Oct; 70(10):1473-5. PubMed ID: 19906350
    [No Abstract]   [Full Text] [Related]  

  • 14. Ketamine affects memory consolidation: differential effects in T-maze and passive avoidance paradigms in mice.
    Wang JH; Fu Y; Wilson FA; Ma YY
    Neuroscience; 2006 Jul; 140(3):993-1002. PubMed ID: 16600517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
    Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
    Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex.
    Pinault D
    Biol Psychiatry; 2008 Apr; 63(8):730-5. PubMed ID: 18022604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamate-based antidepressants: 20 years on.
    Skolnick P; Popik P; Trullas R
    Trends Pharmacol Sci; 2009 Nov; 30(11):563-9. PubMed ID: 19837463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant treatment practice in the face of STAR*D and STEP-BD.
    Cassidy F
    Bipolar Disord; 2008 Dec; 10(8):973-4. PubMed ID: 19594512
    [No Abstract]   [Full Text] [Related]  

  • 19. The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients.
    Cohen SP; Verdolin MH; Chang AS; Kurihara C; Morlando BJ; Mao J
    J Pain; 2006 Jun; 7(6):391-8. PubMed ID: 16750795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants.
    Krystal JH
    Arch Gen Psychiatry; 2010 Nov; 67(11):1110-1. PubMed ID: 21041611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.